G
Graham Jackson
Researcher at St Thomas' Hospital
Publications - 81
Citations - 4662
Graham Jackson is an academic researcher from St Thomas' Hospital. The author has contributed to research in topics: Erectile dysfunction & Sildenafil. The author has an hindex of 33, co-authored 81 publications receiving 4523 citations. Previous affiliations of Graham Jackson include Saint Thomas - West Hospital & Rutgers University.
Papers
More filters
Journal ArticleDOI
Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference)
John B. Kostis,Graham Jackson,Raymond C. Rosen,Elizabeth Barrett-Connor,Kevin L. Billups,Arthur L. Burnett,Culley C. Carson,Melvin D. Cheitlin,Robert F. DeBusk,Vivian Fonseca,Peter Ganz,Irwin Goldstein,André T. Guay,Dimitrios Hatzichristou,Judd E. Hollander,Adolph M. Hutter,Stuart D. Katz,Robert A. Kloner,Murray A. Mittleman,Francesco Montorsi,Piero Montorsi,Ajay Nehra,Richard Sadovsky,Ridwan Shabsigh +23 more
TL;DR: A risk stratification algorithm developed by the First Princeton Consensus Panel corroborates and clarifies the algorithm and emphasizes the importance of risk factor evaluation and management for all patients with ED, and increasing evidence supports the role of lifestyle intervention in ED.
Journal ArticleDOI
Effects of sildenafil citrate on human hemodynamics.
TL;DR: Sildenafil was well tolerated by subjects and patients in all studies, with headache and other symptoms of vasodilation the most commonly reported adverse effects of treatment.
Journal ArticleDOI
REPORT: The Second Princeton Consensus on Sexual Dysfunction and Cardiac Risk: New Guidelines for Sexual Medicine
TL;DR: Recent multinational studies in safety and drug interaction data for three phosphodiesterase type 5 (PDE5) inhibitors are reviewed, with emphasis on the safety of these agents in men with ED and concomitant cardiovascular disease.
Journal ArticleDOI
Why patients do not attend cardiac rehabilitation: role of intentions and illness beliefs
TL;DR: In addition to being older, less aware of their cholesterol values, and less likely to be employed, non-attenders were more likely to believe their condition was controllable and that their lifestyle may have contributed to their illness.
Journal ArticleDOI
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
P. W. Serruys,David P. Foley,Graham Jackson,Hans Bonnier,Carlos Macaya,M. Vrolix,Angelo Branzi,James Shepherd,H. Suryapranata,P. J. De Feyter,Rein Melkert,G. A. Van Es,P J Pfister +12 more
TL;DR: Treatment with fluvastatin 80 mg daily did not affect the process of restenosis and is therefore not indicated for this purpose, however, the observed reduction in mortality and myocardial infarction 40 weeks after PTCA in the fluvasts treated group has not been previously reported with statin therapy.